| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:MK-0952 Sodium CAS:934995-88-7 Package:25mg/RMB 11700;50mg/RMB 15300;100mg/RMB 19500
|
Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- manufacturers
- MK-0952 Sodium
-
- $1670.00 / 25mg
-
2026-04-13
- CAS:934995-88-7
- Min. Order:
- Purity:
- Supply Ability: 10g
|
| | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- Basic information |
| Product Name: | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- | | Synonyms: | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)-;MK-0952 Sodium;MK0952 Sodium,MK 0952 Sodium | | CAS: | 934995-88-7 | | MF: | C28H21FN3NaO4 | | MW: | 505.4722132 | | EINECS: | | | Product Categories: | | | Mol File: | 934995-88-7.mol | ![Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- Structure](CAS/20180808/GIF/934995-88-7.gif) |
| | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- Chemical Properties |
| | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- Usage And Synthesis |
| Uses | MK-0952 sodium is a selective and orally active PDE4 inhibitor, with an IC50 of 0.53 nM. MK-0952 sodium has the potential for Alzheimer’s disease study[1][2]. | | References | [1] Michel Gallant, et al. Discovery of MK-0952, a Selective PDE4 Inhibitor for the Treatment of Long-Term Memory Loss and Mild Cognitive Impairment. Epub 2010 Sep 21. DOI:10.1016/j.bmcl.2010.09.087 [2] Tingting Pan, et al. Dual Functional Cholinesterase and PDE4D Inhibitors for the Treatment of Alzheimer's Disease: Design, Synthesis and Evaluation of tacrine-pyrazolo[3,4-b]pyridine Hybrids. Behav Brain Res. 2016 Apr 15;303:26-33. DOI:10.1016/j.bmcl.2019.06.056 |
| | Cyclopropanecarboxylic acid,
2-[3'-[3-[(cyclopropylaMino)carbonyl]-4-oxo-1,8-naphthyridin-1(4H)-yl]-3-fluoro[1,1'-biphenyl]-4-yl]-, sodiuM salt (1:1), (1R,2R)- Preparation Products And Raw materials |
|